Galectin Therapeutics (GALT) Liabilities and Shareholders Equity (2010 - 2026)

Galectin Therapeutics' Liabilities and Shareholders Equity history runs 17 years deep, the most recent figure standing at $15.8 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 65.4% year-over-year to $15.8 million; the TTM figure through Mar 2026 stood at $63.8 million (down 23.78% YoY), while the FY2025 annual figure was $19.5 million, up 11.64% from the prior year.
• Liabilities and Shareholders Equity was $15.8 million for Q1 2026 at Galectin Therapeutics, down from $19.5 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $33.6 million in Q1 2022 to a low of $9.5 million in Q1 2025.
• Historically, Liabilities and Shareholders Equity has averaged $21.3 million across 5 years, with a median of $20.2 million in 2023.
• The sharpest annual moves came in 2025 and 2026: Liabilities and Shareholders Equity slumped 63.2% in 2025, then jumped 65.4% in 2026.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $21.3 million in 2022, then jumped by 32.49% to $28.2 million in 2023, then tumbled by 37.96% to $17.5 million in 2024, then rose by 11.64% to $19.5 million in 2025, then declined by 19.32% to $15.8 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $15.8 million (Q1 2026), $19.5 million (Q4 2025), and $12.9 million (Q3 2025), per Business Quant data.